Stevanato Group Collaborates with Transcoject to Provide Pre-Fillable Syringe Polymer Options for Pharma
January 24 2023 - 8:00AM
Business Wire
Leading drug containment provider to release a unique
offering including both COP and COC pre-fillable syringes (PFS),
adding to its existing glass PFS portfolio, providing customers
with the broadest choice for PFS
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider
of drug containment and delivery solutions to the pharmaceutical,
biotechnology, and life sciences industries, announced its latest
collaboration with Transcoject GmbH, a medical device and pharma
packaging solutions company. The collaboration will enable
Stevanato Group to add cyclic olefin polymer (COP) and cyclic
olefin copolymer (COC) PFS to its existing portfolio of solutions
providing added value in the customers’ supply chain.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230124005283/en/
(Photo: Business Wire)
By integrating Transcoject's technological know-how with
Stevanato Group’s capabilities and expertise – in drug containment
solutions, manufacturing and market trends - Stevanato Group will
be able to offer pre-fillable syringes in glass and in both COP and
COC polymers.
COP and COC pre-fillable syringes may be usable in a wide range
of applications, including sensitive biologics, mRNA vaccines, and
hyaluronic acid-based drugs. The products’ versatility and
customizability can make them ideal for meeting many compliance
requirements, and they can be seamlessly integrated into existing
fill and finish lines.
“The addition of COP and COC pre-fillable
syringes will uniquely position Stevanato Group to be able to offer
both COC, COP and glass options in the market, empowering customers
to select the best-suited solution to fit their needs from multiple
options”, said Mauro Stocchi, Chief Business Officer at Stevanato
Group. “This is a testament to Stevanato Group’s focus on meeting
market needs through an integrated and comprehensive portfolio of
drug delivery solutions”.
The technology is intended to enable a broad range of format
options from 0.5ml to 200ml, making it adaptable to customers’
specific requirements. Stevanato Group expects the technology to be
ready in 2025 with a first validated product for Luer Lock PFS. In
the interim, Transcoject will support customers by providing
sampling and the companies also intend to utilize their current
capacity to meet demand. A staked-needle PFS version is expected to
be launched in the following years.
“With this cooperation we combine the
strengths of the two companies by bringing together complementary
fields of technologies. We thereby intend to strengthen agility and
flexibility in terms of customers benefit. In addition, we expect
this collaboration to foster innovation and increase value for our
customers. I believe this partnership will strengthen our ability
to offer our customers outstanding pharma packaging solutions”,
emphasized Dr. Christian von Falkenhausen, CEO of Transcoject
GmbH.
The technology will embrace Stevanato Group’s commitment to
conducting business under the principles of sustainability by
embedding sustainability practices, minimizing the consumption of
natural resources, and optimizing the efficiency of the
manufacturing process.
Stevanato Group will unveil the new COP and COC syringe
solutions as Nexa Flex at the Pharmapack Europe conference in
Paris, France, on February 1-2, 2023, at booth no. F46.
Forward-Looking Statements
This press release may include forward-looking statements. The
words “expects”, “planned”, “intended”, “believe”, “will”, “can”
and similar expressions (or their negative) identify certain of
these forward-looking statements. These forward-looking statements
are statements regarding the Companies’ intentions, beliefs or
current expectations concerning the collaboration. The
forward-looking statements in this press release are based on
numerous assumptions regarding the Companies’ present and future
business strategies and the environment in which each Company will
operate in the future. Forward-looking statements involve inherent
known and unknown risks, uncertainties and contingencies because
they relate to events and depend on circumstances that may or may
not occur in the future and may cause the actual results,
performance or achievements of the Companies to be materially
different from those expressed or implied by such forward-looking
statements. Many of these risks and uncertainties relate to factors
that are beyond the Companies' ability to control or estimate
precisely, such as future market conditions, currency fluctuations,
the behavior of other market participants, the actions of
regulators and other factors such as the Companies' ability to
continue to obtain financing to meet its liquidity needs, changes
in the political, social and regulatory framework in which the
Company operates or in economic or technological trends or
conditions. Readers should therefore not place undue reliance on
these statements, particularly not in connection with any contract
or investment decision. Except as required by law, none of the
companies assumes no obligation to update any such forward-looking
statements.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of
drug containment, drug delivery and diagnostic solutions to the
pharmaceutical, biotechnology and life sciences industries. The
Group delivers an integrated, end-to-end portfolio of products,
processes and services that address customer needs across the
entire drug life cycle at each of the development, clinical and
commercial stages. Stevanato Group’s core capabilities in
scientific research and development, its commitment to technical
innovation and its engineering excellence are central to its
ability to offer value added solutions to clients. To learn more,
visit: www.stevanatogroup.com.
About Transcoject
Transcoject was founded in 1969 as one of the first
manufacturers of disposable polymer syringes, and soon expanded its
portfolio to aseptic filling, contract EO sterilization, and
special devices. Since 1995, Transcoject has been developing and
manufacturing customized solutions of prefillable syringes in COP
and COC. The outstanding quality and the widest PFS portfolio from
0.3 ml to 250 ml as well as its flexibility and innovative strength
mark the strong customer and value orientation of the company. See
also: www.transcoject.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230124005283/en/
Stevanato Group: media@stevanatogroup.com Cassie
Gonzalez: stevanatoUS@teamlewis.com Christian von Falkenhausen:
falkenhausen@transcoject.com
Investor Relations Stevanato Group Lisa Miles:
lisa.miles@stevanatogroup.com
Stevanato (NYSE:STVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stevanato (NYSE:STVN)
Historical Stock Chart
From Apr 2023 to Apr 2024